Navigation Links
Nephros Reports 2008 Fourth Quarter and Full Year Financial Results
Date:3/31/2009

is available on the Securities and Exchange Commission's web site at www.sec.gov.

Financial Performance for the Fourth Quarter Ended December 31, 2008 (Unaudited)

For the quarter ended December 31, 2008, Nephros reported net product revenues of approximately $440,000 compared with $441,000 in the corresponding period of 2007, a decrease of $1,000 or 0.2%. The decrease is primarily attributable to an approximate $95,000 decrease in revenue related to sales of the OLpur(TM) MD190 and MD220 products in Europe offset by approximately $93,000 of additional revenue in the fourth quarter of 2008 from its U.S. Defense Department project, which began in 2008.

Operating expenses for the three months ended December 31, 2008 were approximately $969,000 compared with $2,747,000 in the corresponding period of 2007. The decrease of approximately $1,778,000 or 65% is primarily related to the incurrence of accounting, legal and other professional fees associated with the raising of funds in the fourth quarter of 2007 that did not repeat in the comparable period in 2008.

Nephros' net loss was approximately $907,000 or $0.03 per basic and diluted common share for the fourth quarter of 2008 versus a net loss of approximately $21,693,000 or $0.85 per basic and diluted common share in the fourth quarter of 2007. Nephros' net loss decreased $20,786,000 or 96% in the current quarter primarily due to the expenses recognized in 2007 related to the conversion of the Company's notes into Company common stock on November 14, 2007, which did not occur in the comparable 2008 period. Nephros' decrease in net loss per basic and diluted common share during the current quarter was primarily due to the decrease in the net loss compared to the comparable 2007 period as well as the increase in the weighted-average number of shares outstanding from 15,646,286 in the fourth quarter
'/>"/>

SOURCE Nephros, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Nephros Strengthens Commercialization Team with Addition of Marketing Executive
2. Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008
3. Nephros Reports 2008 First Quarter Financial Results
4. Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th
5. Nephros, Inc. Receives the 2009 Frost & Sullivan Medical Device Patient Care Company of the Year Award
6. Nephros Receives Notice of Intention to Delist from AMEX
7. Nephros Common Stock Now Quoted in Pink Sheets
8. Nephros Provides Update on 510k Applications
9. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
10. Haemacure Reports Third Quarter 2007 Results
11. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
(Date:4/23/2014)... scientific director at the National Institute of Arthritis and ... 2014 recipient of the Ross Prize in Molecular Medicine, ... Molecular Medicine . The award will be given on ... in Manhattan, followed by scientific presentations by Dr. O,Shea ... National Institutes of Health. , The award, which includes ...
(Date:4/23/2014)... researchers have developed a way to detect and measure ... gold particles with tails of synthetic DNA., A team ... engineering, used gold nanoparticles to target and bind to ... splice variants, which can indicate the presence and stage ... variants in a cell can be determined by examining ...
(Date:4/23/2014)... falls below normal levels are more likely to have ... disease and type 2 diabetes. A new simple screening ... and possible treatment is described in an article in ... from Mary Ann Liebert, Inc., publishers. The article is ... website at http://www.liebertpub.com/jmh . , ...
(Date:4/23/2014)... evidence mounts showing the potential health benefits of probiotics, ... are taking supplements. And the chemical industry is getting ... health effects could deter growth, so the industry is ... according to the cover story in Chemical & ... the American Chemical Society. , Melody M. Bomgardner, a ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... Mothers, exposure during pregnancy to a class of air ... problems in their children. PAH are,released to air during ... coal, and other,organic material. , The study is the ... problems among school‐age children and two complementary measures of ...
... 21 (HealthDay News) -- Alzheimer,s disease and other types of ... brain, new research indicates. The findings from MRI brain ... to use MRI to predict the progression of dementias and ... San Francisco (UCSF) researchers said. They found that Alzheimer,s ...
... HealthDay Reporter , WEDNESDAY, March 21 (HealthDay ... treatments, alternative therapies such as acupuncture, acupressure and dietary ... sinusitis, a new pilot study suggests. The authors ... explore the potential of combining Western medicine with Eastern ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... epidemic to the United States and the economic value of ... to a new report. The problem is that estimates ... out only 10 years, while it may take much longer ...
... HealthDay Reporter , WEDNESDAY, March 21 (HealthDay News) ... in people already taking statins such as Lipitor, making ... alternative, a preliminary new study suggests. Two single-dose ... a group with high cholesterol showed that the drug, ...
... led by A. K. Rajasekaran, PhD, Director of the Nemours ... protein involved in cell function and regulation is stopped by ... published online in the American Journal of Physiology - ... is well recognized as a cause of lung cancer and ...
Cached Medicine News:Health News:Prenatal exposure to combustion-related pollutants and anxiety, attention problems in young children 2Health News:Alternative Medicine May Help Ease Chronic Sinusitis 2Health News:Alternative Medicine May Help Ease Chronic Sinusitis 3Health News:U.S. Underestimates Long-Term Costs of Obesity, Experts Say 2Health News:U.S. Underestimates Long-Term Costs of Obesity, Experts Say 3Health News:Statin Alternative Looks Promising in Early Trials 2Health News:Statin Alternative Looks Promising in Early Trials 3Health News:Nemours researchers uncover new evidence of cancer-causing agent present in gaseous phase of cigarette smoke 2
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 6 Physicians Interactive (PI), a leading ... today announced a partnership with OPTIMIZERx Corp ... healthcare professionals with SampleMD, a solution that  allows for ... vouchers, prescription co-pay coupons and other support information directly ...
... 6 e-MDs, an industry leader in the ... and practice management (PM) solutions,  congratulates  the Diabetes ... Medicine of Fort Collins, CO, for their recognition ... Excellence recipients.  The Healthcare Information and Management Systems ...
Cached Medicine Technology:Physicians Interactive Launches Partnership with SampleMD to Expand Sampling Options for Clinicians and Reduce Costs for Patients 2Physicians Interactive Launches Partnership with SampleMD to Expand Sampling Options for Clinicians and Reduce Costs for Patients 3e-MDs Clients Win HIMSS Davies Awards of Excellence 2e-MDs Clients Win HIMSS Davies Awards of Excellence 3e-MDs Clients Win HIMSS Davies Awards of Excellence 4
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... Immuno Concepts manufactures slides that are compatible ... to decrease the number of pipetting steps ... sample dilutions on the slides. Ask Immuno ... and these slides. These slide formats are ...
... HEp-2000 ANA uses a patented HEp-2 cell ... increase the sensitivity to SS-A/Ro autoantibodies, without ... independent studies have been published worldwide on ... sensitivity to SS-A/Ro autoantibodies when used in ...
... and ENA assays can be used ... antinuclear antibodies, which are associated with ... Systemic lupus erythematosus (Lupus), Sjgren's syndrome, ... sclerosis, scleroderma, polymyositis, dermatomyositis, and Raynaud's ...
Medicine Products: